Skip to main content

12-11-2021 | ACR 2021 | Conference coverage | Video

Olokizumab: What makes it an effective and novel treatment for RA?

Roy Fleischmann discusses the implications of the CREDO2 and 3 trial findings looking at olokizumab efficacy versus adalimumab as an add-on to methotrexate and in TNF inhibitor non-responders (3:15).

Read transcript

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Image Credits